These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38460433)

  • 21. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
    Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
    Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial.
    He XY; Elson P; Pohlman B; Lichtin A; Hussein M; Andresen S; Kalaycio M
    BMC Cancer; 2002 May; 2():12. PubMed ID: 12019034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.
    Advani AS; Cooper B; Visconte V; Elson P; Chan R; Carew J; Wei W; Mukherjee S; Gerds A; Carraway H; Nazha A; Hamilton B; Sobecks R; Caimi P; Tomlinson B; Malek E; Little J; Miron A; Pink J; Maciejewski J; Unger A; Kalaycio M; de Lima M; Sekeres MA
    Clin Cancer Res; 2019 Jul; 25(14):4231-4237. PubMed ID: 30992301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).
    Advani R; Visani G; Milligan D; Saba H; Tallman M; Rowe JM; Wiernik PH; Ramek J; Dugan K; Lum B; Villena J; Davis E; Paietta E; Litchman M; Covelli A; Sikic B; Greenberg P
    Adv Exp Med Biol; 1999; 457():47-56. PubMed ID: 10500779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy.
    Mühleck R; Scholl S; Hilgendorf I; Schrenk K; Hammersen J; Frietsch JJ; Fleischmann M; Sayer HG; Glaser A; Hochhaus A; Schnetzke U
    J Cancer Res Clin Oncol; 2022 Sep; 148(9):2539-2548. PubMed ID: 34609595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience.
    Vignetti M; Orsini E; Petti MC; Moleti ML; Andrizzi C; Pinto RM; Amadori S; Meloni G
    Ann Oncol; 1996 Nov; 7(9):933-8. PubMed ID: 9006744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.
    DeAngelo DJ; Brunner AM; Werner L; Avigan D; Fathi AT; Sperling AS; Washington A; Stroopinsky D; Rosenblatt J; McMasters M; Luptakova K; Wadleigh M; Steensma DP; Hobbs GS; Attar EC; Amrein PC; Ebert BL; Stone RM; Ballen KK
    Am J Hematol; 2018 Feb; 93(2):254-261. PubMed ID: 29119643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
    Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
    Tenold ME; Moskoff BN; Krishnan R; Rosenberg AS; Hoeg RT; Abedi M; Tuscano JM; Jonas BA
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e611-e618. PubMed ID: 33811007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.
    Yamamoto C; Ito S; Mashima K; Umino K; Minakata D; Yamasaki R; Kawasaki Y; Sugimoto M; Nakano H; Ashizawa M; Okazuka K; Hatano K; Sato K; Oh I; Fujiwara S; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Leuk Lymphoma; 2016 Nov; 57(11):2541-7. PubMed ID: 26917050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
    Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y
    Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
    Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
    J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party.
    Ahn JS; Yang DH; Jung SH; Lee JJ; Kim I; Park S; Chung JS; Shin HJ; Kim DY; Lee KH; Moon JH; Sohn SK; Song IC; Jo DY; Joo YD;
    Acta Haematol; 2015; 133(1):91-7. PubMed ID: 25171064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
    McLaughlin B; Im A; Raptis A; Agha M; Hou JZ; Redner R; Duggal S; Lin Y; Smith C; Boyiadzis M
    Int J Hematol; 2012 Dec; 96(6):743-7. PubMed ID: 23132594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.
    Kohrt HE; Patel S; Ho M; Owen T; Pollyea DA; Majeti R; Gotlib J; Coutre S; Liedtke M; Berube C; Alizadeh AA; Medeiros BC
    Am J Hematol; 2010 Nov; 85(11):877-81. PubMed ID: 20872554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia.
    Lazzarino M; Morra E; Alessandrino EP; Orlandi E; Pagnucco G; Merante S; Bernasconi P; Inverardi D; Bonfichi M; Bernasconi C
    Eur J Haematol; 1989 Nov; 43(5):411-6. PubMed ID: 2612614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
    Wang AY; Weiner H; Green M; Chang H; Fulton N; Larson RA; Odenike O; Artz AS; Bishop MR; Godley LA; Thirman MJ; Kosuri S; Churpek JE; Curran E; Pettit K; Stock W; Liu H
    J Hematol Oncol; 2018 Jan; 11(1):4. PubMed ID: 29304833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
    Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.